search
Back to results

Effect of a CCK-1R Agonist on Food Intake in Humans (GSK)

Primary Purpose

Bulimia

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
GSKI181771X (CCK-1R agonist)
Instructions to binge eat
Instructions to eat normally
Placebo
Sponsored by
St. Luke's-Roosevelt Hospital Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Bulimia focused on measuring Eating, Food Intake, Appetite

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Both controls and patients will be female, 18 to 45 years old, and within 80-120% of ideal body weight (Metropolitan Life Insurance, 1983). Inclusion and exclusion will be evaluated using the following guidelines:

Normal Controls:

  • No current or past psychiatric illness
  • No history of binge eating or vomiting
  • 80-120% ideal weight
  • Of non-childbearing potential (i.e. physiologically incapable of becoming pregnant or surgically sterile)
  • If of childbearing potential, willing to use an acceptable method of birth-control (please see list in "Exclusion" section)

Patients with Bulimia Nervosa:

  • DSM-IV (diagnostic statistical manual - American Psychiatric Association) criteria for bulimia nervosa
  • Duration of illness > 1 year
  • Purging after binges via self-induced vomiting

(Same as controls for remaining inclusion criteria)

Exclusion Criteria:

Normal Controls:

  • Significant medical illness: CBC, Chem-1, serum electrolytes (sodium, potassium, chloride, CO2), glucose, BUN (blood urea nitrogen), creatinine, Alk Phos, ALT (SGPT), AST (SGOT), LDH, total bilirubin, total protein, albumin, globulin, A/G ratio, calcium, phosphorus, uric acid, cholesterol, triglyceride
  • ALT outside of upper limit of normal: Chem-1
  • History of gallstones, pancreatitis or cholecystitis
  • Current medication
  • Hypersensitivity to benzodiazepines (contraindication in DCSI v02, 1-March-2006)
  • Drug or alcohol abuse in last 3 mts
  • Pregnancy
  • Unable or unwilling to use highly effective methods of contraception for the duration of the study until an insignificant amount of the investigational product remains in the subject (i.e. at least 5 terminal phase half-lives). Examples of highly effective methods of contraception are:

    • Implants of levonorgestrel, or
    • Injectable progestogen, or
    • Oral birth control pills for at least 3 monthly cycles prior to administration of study drug + continuation for 24 hrs after last dose of study drug, or
    • Double-barrier method (e.g. condom, diaphragm) with spermicide

Note-Significant medical illness is any illness requiring continued care, i.e. chronic medication. Examples include hypertension, diabetes, and systemic lupus erythematosis. Subjects with seasonal allergies or occasional urinary tract infections will be included.

Patients with Bulimia Nervosa:

  • Same as controls

Sites / Locations

  • St. Luke's/Roosevelt Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Placebo Comparator

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Active Comparator

Arm Label

1 'Instructions to eat normally'

2 'Instructions to eat normally'

3 'Instructions to eat normally'

4 'Instructions to eat normally'

5 'Instructions to eat normally'

6 'Instructions to eat normally'

7 Instructions to binge eat

8 Instructions to binge eat

Arm Description

'Instructions to eat normally' Placebo 1 mg dose

'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'

'Instructions to eat normally' 2 mg placebo

'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'

'Instructions to eat normally' 4 mg placebo

'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'

Instructions to binge eat 4 mg placebo

Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'

Outcomes

Primary Outcome Measures

Food Intake for 4 mg Dose of CCK Agonist vs Placebo Meal Conditions
Food Intake at 25-30 min after having drug or placebo under normal and binge eating instructions

Secondary Outcome Measures

Fullness Rating
rating of "How full do you feel" by marking the feeling on a 150 mm line anchored at one end from 0 (not at all) to 150 (most imaginable).
Sickness Report
Response to question "How sick do you feel" measured on a 150 mm line anchored by none at all (0 mm left end) and extremely (150 mm right end)

Full Information

First Posted
January 14, 2008
Last Updated
April 26, 2017
Sponsor
St. Luke's-Roosevelt Hospital Center
Collaborators
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT00600743
Brief Title
Effect of a CCK-1R Agonist on Food Intake in Humans
Acronym
GSK
Official Title
Effect of a CCK-1R Agonist on Food Intake in Humans
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Terminated
Why Stopped
Drug expired before was completed.
Study Start Date
January 2008 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
February 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Luke's-Roosevelt Hospital Center
Collaborators
GlaxoSmithKline

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.
Detailed Description
This study tests the hypothesis that an oral CCK antagonist GSKI181771X will reduce the size of a binge meal. It was intended to study the effects of increasing doses on antagonist on normal individuals to find an effective dose in a non-binge meal before moving to a binge meal. Once the effects of the antagonist on a binge meal were found, the compound would be used on patients with bulimia nervosa. However, the product expired and more was not available before the patients were tested. Data are presented for the normal participants who were instructed to eat normally, followed by a group that was instructed to binge eat. Comparisons were made between groups with different instructions and between binge and normal meals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bulimia
Keywords
Eating, Food Intake, Appetite

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1 'Instructions to eat normally'
Arm Type
Placebo Comparator
Arm Description
'Instructions to eat normally' Placebo 1 mg dose
Arm Title
2 'Instructions to eat normally'
Arm Type
Active Comparator
Arm Description
'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
Arm Title
3 'Instructions to eat normally'
Arm Type
Placebo Comparator
Arm Description
'Instructions to eat normally' 2 mg placebo
Arm Title
4 'Instructions to eat normally'
Arm Type
Active Comparator
Arm Description
'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
Arm Title
5 'Instructions to eat normally'
Arm Type
Placebo Comparator
Arm Description
'Instructions to eat normally' 4 mg placebo
Arm Title
6 'Instructions to eat normally'
Arm Type
Active Comparator
Arm Description
'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
Arm Title
7 Instructions to binge eat
Arm Type
Placebo Comparator
Arm Description
Instructions to binge eat 4 mg placebo
Arm Title
8 Instructions to binge eat
Arm Type
Active Comparator
Arm Description
Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'
Intervention Type
Drug
Intervention Name(s)
GSKI181771X (CCK-1R agonist)
Other Intervention Name(s)
GSKI181771X
Intervention Description
Drug one trial vs placebo
Intervention Type
Behavioral
Intervention Name(s)
Instructions to binge eat
Intervention Description
Subjects will be instructed to binge eat and will also be given either drug or placebo
Intervention Type
Behavioral
Intervention Name(s)
Instructions to eat normally
Intervention Description
Subjects will be instructed to eat normally and will also be given either drug or placebo
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Drug one trial vs placebo
Primary Outcome Measure Information:
Title
Food Intake for 4 mg Dose of CCK Agonist vs Placebo Meal Conditions
Description
Food Intake at 25-30 min after having drug or placebo under normal and binge eating instructions
Time Frame
25-30 min after taking drug
Secondary Outcome Measure Information:
Title
Fullness Rating
Description
rating of "How full do you feel" by marking the feeling on a 150 mm line anchored at one end from 0 (not at all) to 150 (most imaginable).
Time Frame
25-30 min after taking drug
Title
Sickness Report
Description
Response to question "How sick do you feel" measured on a 150 mm line anchored by none at all (0 mm left end) and extremely (150 mm right end)
Time Frame
25-30 min after drug or placebo

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Both controls and patients will be female, 18 to 45 years old, and within 80-120% of ideal body weight (Metropolitan Life Insurance, 1983). Inclusion and exclusion will be evaluated using the following guidelines: Normal Controls: No current or past psychiatric illness No history of binge eating or vomiting 80-120% ideal weight Of non-childbearing potential (i.e. physiologically incapable of becoming pregnant or surgically sterile) If of childbearing potential, willing to use an acceptable method of birth-control (please see list in "Exclusion" section) Patients with Bulimia Nervosa: DSM-IV (diagnostic statistical manual - American Psychiatric Association) criteria for bulimia nervosa Duration of illness > 1 year Purging after binges via self-induced vomiting (Same as controls for remaining inclusion criteria) Exclusion Criteria: Normal Controls: Significant medical illness: CBC, Chem-1, serum electrolytes (sodium, potassium, chloride, CO2), glucose, BUN (blood urea nitrogen), creatinine, Alk Phos, ALT (SGPT), AST (SGOT), LDH, total bilirubin, total protein, albumin, globulin, A/G ratio, calcium, phosphorus, uric acid, cholesterol, triglyceride ALT outside of upper limit of normal: Chem-1 History of gallstones, pancreatitis or cholecystitis Current medication Hypersensitivity to benzodiazepines (contraindication in DCSI v02, 1-March-2006) Drug or alcohol abuse in last 3 mts Pregnancy Unable or unwilling to use highly effective methods of contraception for the duration of the study until an insignificant amount of the investigational product remains in the subject (i.e. at least 5 terminal phase half-lives). Examples of highly effective methods of contraception are: Implants of levonorgestrel, or Injectable progestogen, or Oral birth control pills for at least 3 monthly cycles prior to administration of study drug + continuation for 24 hrs after last dose of study drug, or Double-barrier method (e.g. condom, diaphragm) with spermicide Note-Significant medical illness is any illness requiring continued care, i.e. chronic medication. Examples include hypertension, diabetes, and systemic lupus erythematosis. Subjects with seasonal allergies or occasional urinary tract infections will be included. Patients with Bulimia Nervosa: Same as controls
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harry R. Kissileff, Ph.D.
Organizational Affiliation
St. Luke's-Roosevelt Hospital Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jeanine Albu, MD
Organizational Affiliation
St. Luke's-Roosevelt Hospital Center
Official's Role
Study Director
Facility Information:
Facility Name
St. Luke's/Roosevelt Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10025
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.nyorc.org
Description
studies

Learn more about this trial

Effect of a CCK-1R Agonist on Food Intake in Humans

We'll reach out to this number within 24 hrs